スポンサーリンク
Department of Immunology | 論文
- Analysis of tumor necrosis factor-α production and polymorphisms of the tumor necrosis factor-α gene in individuals with a history of Kawasaki disease
- Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b^+ HLA-A24^+ patients
- Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer
- Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor-rejection Antigen SART-1
- Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer
- Cytotoxicity Induced by Erythrina variegata Serine Proteinase Inhibitors in Tumor Hematopoietic Stem Cell Lines
- Personalized peptide vaccines : A new therapeutic modality for cancer
- Expression of Tumor-rejection Antigens in Gynecologic Cancers
- Expression of the SART-1 Antigens in Uterine Cancers
- Target molecules in specific immunotherapy against prostate cancer
- Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24^+ prostate cancer patients
- Histocompatibility Leukocyte Antigen-A2-restricted and Tumor-specific Cytotoxic T Lymphocytes from Tumor-infiltrating Lymphocytes of a Patient with Testicular Embryonal Cancer
- Expression of MAGE-1 Gene by Esophageal Carcinomas
- Histocompatibility Leukocyte Antigen-A2402-restricted Cytotoxic T Lymphocytes Recognizing Adenocarcinoma in Tumor-infiltrating Lymphocytes of Patients with Colon Cancer
- Expression of SART3 Tumor-rejection Antigen in Gastric Cancers
- Changes in the Mononuclear Cell Subpopulations of Rat Cardiac Transplant Recipients Administered FK506 for the Treatment of Ongoing Rejection
- Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
- Antibody Reactive to a Hepatitis C Virus (HCV)-Derived Peptide Capable of Inducing HLA-A2 Restricted Cytotoxic T Lymphocytes Is Detectable in a Majority of HCV-Infected Individuals without HLA-A2 Restriction
- Chemohormonal therapy as primary treatment for metastatic prostate cancer : A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist
- Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide